Practical Dermatology Focuses on Inflammation in Acne…And Strategies to Clear Skin

WAYNE, Pa. - Sept. 4, 2013 - PRLog -- “How Should I Be Treating Acne in 2013?” Practical Dermatology (http://bmctoday.net/practicaldermatology/) answers that question and more in the current edition, which explores the latest approaches to acne care. Experts discuss the use of various therapies, including adapalene 0.1% and benzoyl peroxide 2.5% gel (Epiduo, Galderma), adapalene 0.3% (Differin, Galderma), dapsone gel 5% (Aczone, Allergan), benzoyl peroxide, and oral contraceptive pills. In exclusive related videos, available only at DermTube.com, Andrew Krakowski, MD discusses new pediatric acne treatment guidelines and Julie C. Harper addresses the challenges of treating adult female acne patients.

In an overview of device-based approaches to acne care, Michael H. Gold, MD emphasizes the need for good skincare, while reviewing the use of light-based acne therapies like BLU-U (DUSA),Isolaz (Solta Medical), and Aclera (Palomar Medical). Dr. Gold also touches on the management of acne scarring, noting that “Typically, we use fractional technology, whether non-ablative (four to six treatments done every month), ablative fractional treatments (one to two total treatments), or sublative fractional technology—bipolar RF therapy (two to three treatments on average). Sublative technology using the eMatrix from Syneron, has helped many patients of all skin types improve their acne scars with minimal downtime.” Ablative fractional devices, such as Lumenis’ UltraPulse and AcuPulse devices, as well as the Syneron CoRE2 device, are also helpful, he says.

On the heels of FDA approval of Mirvaso (Galderma), Diane S. Berson, MD discusses the potential role for brimonidine in rosacea care. “We have never had a topical that actually dealt with the vascular component of rosacea. And what we have in the pipeline are a couple of agents that are actually alpha agonists, which will cause vasoconstriction and in so doing help decrease the redness for these patients. They seem to work really fast and their effect lasts all day, and so far phase II trials have shown no tachyphylaxis.”